Significant discrepancies exist when comparing cancer treatment approaches in the America and Western Europe. The American model, generally characterized by for-profit insurance and a priority on innovation, often leads to early introduction of cutting-edge therapies, albeit at a significantly greater cost. In contrast, European systems frequently